For many African Americans with hepatitis C, treatment doesn’t work. Telaprevir, an experimental drug, may change that.

In trials, even some people who had failed to clear hep C in previous treatment succeeded when telaprevir was added to the usual regimen (pegylated interferon plus ribavirin). Adding telaprevir also shortened treatment time for some people.

The FDA might approve telaprevir this year.